Compare CIGI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIGI | CRSP |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 1995 | 2016 |
| Metric | CIGI | CRSP |
|---|---|---|
| Price | $109.31 | $51.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $176.25 | $70.29 |
| AVG Volume (30 Days) | 174.5K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $17.28 | $807.72 |
| Revenue Next Year | $8.30 | $172.52 |
| P/E Ratio | $57.57 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $95.66 | $33.03 |
| 52 Week High | $171.20 | $78.48 |
| Indicator | CIGI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 45.02 |
| Support Level | $97.32 | $44.82 |
| Resistance Level | $120.37 | $60.45 |
| Average True Range (ATR) | 3.50 | 2.88 |
| MACD | -0.05 | -0.30 |
| Stochastic Oscillator | 13.32 | 12.29 |
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.